RRAS2

RRAS2 Full Name

related RAS viral (r-ras) oncogene homolog 2

RRAS2 Introduction

Related RAS viral (r-ras) oncogene homolog 2 (RRAS2), also known as TC21, is a member of the Ras family of small GTPases that functions as a molecular switch controlling cell proliferation, survival, adhesion, migration, and intracellular signal transduction. Similar to KRAS, HRAS, and NRAS, RRAS2 alternates between inactive GDP-bound and active GTP-bound states to regulate downstream signaling pathways, particularly the PI3K-AKT and MAPK/ERK cascades. However, accumulating evidence indicates that RRAS2 is not simply a redundant RAS protein. Instead, it performs distinct biological functions in maintaining cell growth, cytoskeletal organization, and adhesive behavior. Recent genetic studies demonstrated that endogenous RRAS2 is essential for sustaining PI3K-AKT signaling and normal proliferative capacity, while activated RRAS2 suppresses TP53-mediated cell cycle arrest through coordinated PI3K, mTORC, and MEK/ERK signaling. These findings have established RRAS2 as an independent signaling regulator with growing importance in cancer biology and targeted therapy research.

Beyond its role in cell growth, RRAS2 serves as a critical regulator of focal adhesion dynamics, metabolic adaptation, and interactions between cells and the extracellular matrix. Unlike classical RAS proteins that primarily localize to the plasma membrane, endogenous RRAS2 preferentially accumulates at focal adhesions, allowing it to coordinate integrin signaling, cell adhesion, migration, and invasion. Cancer-associated RRAS2 mutations, particularly the recurrent Q72L hotspot mutation, exhibit strong transforming activity and sustain PI3K and ERK pathway activation in multiple tumor models. RRAS2 also regulates gene expression programs associated with inflammation, immune responses, mitochondrial respiration, and extracellular matrix remodeling. Recent studies further identified RRAS2 as a central signaling hub in mammary gland development and triple-negative breast cancer metabolism, demonstrating that overexpression of wild-type RRAS2 alone can initiate mammary tumor formation, while RRAS2 deficiency impairs normal mammary development and alters tumor metabolic behavior.

RRAS2 has emerged as a clinically relevant oncogenic driver in several human malignancies, including non-small cell lung cancer, breast cancer, ovarian cancer, and certain hematological cancers. Large-scale genomic analyses have identified recurrent activating RRAS2 mutations that function independently of other MAPK pathway drivers, suggesting that RRAS2 represents a distinct molecular subtype of RAS-driven cancer. Preclinical studies have shown that tumors harboring RRAS2 mutations are highly responsive to the pan-RAS inhibitor RMC-6236, which effectively suppresses MAPK signaling, induces apoptosis, and inhibits tumor growth in vivo. In addition, RRAS2 silencing has been reported to enhance the sensitivity of breast cancer cells to tamoxifen, highlighting its potential role in overcoming therapeutic resistance. As precision oncology expands beyond canonical KRAS mutations, RRAS2 is increasingly recognized as both a promising therapeutic target and a predictive biomarker for patient stratification, making it an important focus for future studies aimed at developing more effective targeted cancer therapies.

Alternate Names for RRAS2

RRAS2; related RAS viral (r-ras) oncogene homolog 2; TC21; ras-related protein R-Ras2; ras-like protein TC21; teratocarcinoma oncogene

• 1.Fernández-Pisonero I, et al.; Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins. Oncogene. 2025, 44(24):1905-1921.
  2.Clavaín L, et al.; Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors. Oncogene. 2023, 42(5):389-405.